DelSiTech Ltd, a drug delivery and drug development company based in Finland announced significant grant funding to support the development of long-acting controlled release formulations for family planning as well as for human immunodeficiency virus (HIV) antivirals, from the Bill & Melinda Gates Foundation.

DelSiTech is the global leader in advanced silica-based, sustained and controlled release delivery technologies for administration of injectable, implant and topical eye drop dosage forms. Its technology offers long-acting injectable medical solutions to enable longer treatment periods and fewer injections.

DelSiTech^TM Silica Matrix technology allows the drug substances, ranging from small molecules to biologics to be encapsulated in matrix microparticles, providing stability for the drug substance and a true controlled long-acting release based on the matrix dissolution. This allows the injection to release a stabilized product for months or over a year.